论文部分内容阅读
目的 :观察和分析阿司匹林在有脑出血(CH)史缺血性脑卒中(IS)复发患者中的预防效果及安全性。方法:选取100例具有CH史的IS患者作为观察组,选取100例无CH史的IS患者作为对照组,对两组患者均在常规疗法的基础上给予阿司匹林抗血小板治疗,对两组患者治疗前、治疗后1周、治疗后1个月、治疗后6个月的血脂指标、临床疗效及并发症发生情况进行观察和比较。结果 :从治疗后1周开始,两组患者的各项血脂指标均较治疗前有了显著的改善,而两组患者各项血脂指标的组间差异、疗效构成和临床有效率的差异均无统计学意义;观察组患者并发症的总发生率显著高于对照组,但两组患者各项并发症的发生率的差异均无统计学意义。结论 :对于具有CH病史的IS患者应用阿司匹林抗血小板治疗,其临床疗效与在初发IS患者中应用时基本等同,而且不会显著增加IS和CH的复发率,具有较好的安全性。
Objective: To observe and analyze the preventive effect and safety of aspirin in the patients with recurrent cerebral hemorrhage (CH) and ischemic stroke (IS). Methods: One hundred patients with IS history of CH were selected as the observation group, 100 IS patients without CH history were selected as the control group, aspirin antiplatelet therapy was given to both groups on the basis of conventional therapy, Before treatment, 1 week after treatment, 1 month after treatment, 6 months after treatment, blood lipid indicators, clinical efficacy and complications were observed and compared. Results: From the first week after treatment, the blood lipid indexes of the two groups were significantly improved compared with those before treatment. There was no significant difference between the two groups in the differences of the blood lipid indexes, the composition of the efficacy and the clinical effective rate The total incidence of complication in the observation group was significantly higher than that in the control group, but there was no significant difference in the incidence of complications between the two groups. CONCLUSIONS: Aspirin antiplatelet therapy in IS patients with a history of CH is almost equivalent in clinical application to those in patients with initially diagnosed IS and does not significantly increase the relapse rate of IS and CH with good safety.